Psoriasis Treatments
Find Psoriasis Treatments
Generic Name
Ustekinumab
Brand Names
Ustekinumab-AAUZ, Pyzchiva, Yesintek, Otulfi, Selarsdi, Ustekinumab-aekn, Starjemza, Wezlana, Steqeyma, Ustekinumab-TTWE, Stelara
FDA approval date: September 25, 2009
Classification: Interleukin-12 Antagonist
Form: Injection, Solution
What is Ustekinumab-AAUZ (Ustekinumab)?
SELARSDI is a human interleukin-12 and -23 antagonist indicated for the treatment of: Adult patients with: moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.
Save this treatment for later
Not sure about your diagnosis?
Tired of the same old research?
Related Clinical Trials
A Non-interventional, Multi-centric, Single Country Observational Study to Assess the Safety and Effectiveness of Guselkumab After Ustekinumab (Originator or Biosimilar) in Moderate to Severe Psoriasis Patients in Clinical Routine
Summary: The purpose of this study is to assess the effectiveness and safety of guselkumab following a switch from ustekinumab or an ustekinumab biosimilar in participants with moderate to severe psoriasis, a chronic inflammatory skin disease characterized by erythematous, scaly plaques that may be associated with pain and pruritus, in routine clinical practice.
Efficacy of Guselkumab in Chinese Participants With Crohn's Disease Following Loss of Response to Ustekinumab
Summary: The purpose of this study is to evaluate how well guselkumab works in participants with Crohn's disease (CD; a long-term condition causing severe inflammation of the intestinal tract) who no longer respond to treatment with ustekinumab.
A Phase 3b/4 Multi-center, Randomized, Open-label, Long-term Safety Study of Deucravacitinib in Comparison to Ustekinumab in Participants With Moderate-to-Severe Plaque Psoriasis
Summary: A study to evaluate the long-term safety of Deucravacitinib versus Ustekinumab in participants with psoriasis